Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
The company has received approval from DCGI to begin patient enrolment and dosing in the country
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
Triggering global regulatory submissions this year for the treatment of obesity
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Subscribe To Our Newsletter & Stay Updated
